ClinicalTrials.gg
TerminatedNCT03180762Updated Oct 30, 2018

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

A Phase 1 interventional study of JNJ-64140284 0.1 mg and JNJ-64140284 0.5 mg in Healthy, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

How we know

Why this study was terminated
Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration (ascending dose levels) under fasted condition, to characterize the pharmacokinetics (PK) of JNJ-64140284 in plasma, cerebrospinal fluid (CSF) and urine after single oral dose administration and to investigate the effect of food (high fat/high calorie) on the PK of JNJ-64140284 following single oral dose administration.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1 and 2:

  • Healthy male participants between 18 and 58 years of age, inclusive

Part 1, 2 and 3:

  • Participants must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed once during the screening phase. The participant may be included only if the investigator judges the abnormalities or deviations from normal to be not or to be appropriate and reasonable for the population under study according to both the investigator and to the Janssen Safety Physician, are acceptable

Part 3:

  • Healthy male and female participants between 59 and 75 years of age, inclusive
  • Participants must be healthy and medically stable on the basis of clinical laboratory tests (at screening) and physical and neurological examination (at screening and at admission to the clinical unit). If the participant is medically stable with medication, inclusion can be allowed on a case by case basis with written agreement of the sponsor's responsible safety physician
  • Women must not be of (must be with amenorrhea for at least 12 months) or permanently sterilized (for example, tubal occlusion, hysterectomy, bilateral salpingectomy)

Exclusion criteria

Exclusion Criteria:

Part 1, 2 and 3:

  • Participants with a history of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the participant
  • Participants with a serology positive for surface antigen (HBsAg), virus (HCV) antibodies or (HIV) antibodies
  • Participants with a acute illness within 7 days prior to study drug administration
  • Donation of 1 or more units (approximately 450 milliliter [mL]) of blood or acute loss of an equivalent amount of blood within 90 days prior to study drug administration

Part 3:

  • participants having a for spinal puncture including:
  1. A relevant history of lower back pain or scoliosis or kyphosis and/or major (lumbar) back surgery (microdiscectomy is allowed) in the opinion of the investigator
  2. Allergy to local anesthetics and/or iodine/disinfectants
  3. Clinically significant abnormal values for coagulation at screening
  4. Use of aspirin (even low dose) within 5 days prior to lumbar puncture
  5. Use of low molecular weight heparin (LMWH) within 12 hours prior to lumbar puncture
  6. Use of any anticoagulant treatment (besides LMWH described above) within 1 week prior to lumbar puncture
  7. Has a topical infection or local dermatological condition at the puncture site prior to puncture
  8. Has papilloedema or signs of increased intracranial pressure based on fundoscopy at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1 (JNJ-64140284 or Placebo)

    Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 0.1 mg · Drug: Placebo

  • Experimental
    Part 1: Cohort 2 (JNJ-64140284 or Placebo)

    Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 0.5 mg · Drug: Placebo

  • Experimental
    Part 1: Cohort 3 (JNJ-64140284 or Placebo)

    Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 2.5 mg · Drug: Placebo

  • Experimental
    Part 1: Cohort 4 (JNJ-64140284 or Placebo)

    Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 10 mg · Drug: Placebo

  • Experimental
    Part 1: Cohort 5 (JNJ-64140284 or Placebo)

    Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 50 mg · Drug: Placebo

  • Experimental
    Part 1: Cohort 6 (JNJ-64140284 or Placebo)

    Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.

    Drug: JNJ-64140284 150 mg · Drug: Placebo

  • Experimental
    Part 2: Cohort 7 (JNJ-64140284)

    Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics \[PK\] of preceding dose levels; no more than 50 percent (%) of the highest dose tested \[though as high as possible within this restriction\] and considered well tolerated in Part 1) under fed conditions on Day 1.

    Drug: JNJ-64140284 (dose to be determined [TBD])

  • Experimental
    Part 3: Cohort 8 (JNJ-64140284 or Placebo)

    Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.

    Drug: JNJ-64140284 (dose to be determined [TBD]) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability: Part 1, Part 2, and Part 3

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Approximately 40 days

  2. Maximum Plasma Concentration (Cmax) of JNJ-64140284: Part 1, Part 2, and Part 3

    The Cmax is the maximum observed plasma concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  3. Maximum Cerebrospinal Fluid (CSF) Concentration (Cmax) of JNJ-64140284: Part 3

    The Cmax is the maximum observed CSF concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  4. Last Quantifiable Plasma Concentration (Clast) of JNJ-64140284: Part 1, Part 2, and Part 3

    The Clast is the last quantifiable plasma concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  5. Last Quantifiable CSF Concentration (Clast) of JNJ-64140284: Part 3

    The Clast is the last quantifiable CSF concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  6. Time to Reach Maximum Plasma Concentration (Tmax) of JNJ-64140284: Part 1, Part 2, and Part 3

    The Tmax is defined as actual sampling time to reach maximum observed plasma concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  7. Time to Reach Maximum CSF Concentration (Tmax) of JNJ-64140284: Part 1, Part 2, and Part 3

    The Tmax is defined as actual sampling time to reach maximum observed CSF concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  8. Time of the Last Quantifiable Plasma Concentration (Tlast) of JNJ-64140284: Part 1, Part 2, and Part 3

    The Tlast is defined as the time of the last quantifiable plasma concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  9. Time of the Last Quantifiable CSF Concentration (Tlast) of JNJ-64140284: Part 3

    The Tlast is defined as the time of the last quantifiable CSF concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  10. Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC [0-last]) of JNJ-64140284: Part 1, Part 2, and Part 3

    The (AUC \[0-last\]) is the area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  11. Area Under the CSF Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC [0-last]) of JNJ-64140284: Part 1, Part 2, and Part 3

    The (AUC \[0-last\]) is the area under the CSF concentration-time curve from time 0 to time of the last quantifiable concentration.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  12. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-64140284: Part 1, Part 2, and Part 3

    The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(0-last) and C(0-last)/lambda(z), wherein AUC(0-last) is the area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentrations; C(0-last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  13. Area Under the CSF Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-64140284: Part 3

    The AUC (0-infinity) is the area under the CSF concentration-time curve from time zero to infinite time, calculated as the sum of AUC(0-last) and C(0-last)/lambda(z), wherein AUC(0-last) is the area under the CSF concentration-time curve from time 0 to time of the last quantifiable concentrations; C(0-last) is the last observed quantifiable concentration; and lambda(z) is elimination rate constant.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose

  14. Elimination Rate Constant (Lambda[z]) of JNJ-64140284: Part 1, Part 2, and Part 3

    Lambda(z) is first-order rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  15. Elimination Half-life (t1/2) of JNJ-64140284: Part 1, Part 2, and Part 3

    The t1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post dose

  16. Total Clearance (CL/F) of JNJ-64140284: Part 1, Part 2, and Part 3

    CL/F is the total clearance of drug after extravascular administration, uncorrected for absolute bioavailability.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  17. Creatinine Clearance (CLcr) of JNJ-64140284: Part 1, Part 2, and Part 3

    CLcr will be determined with the Cockcroft-Gault formula.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose

  18. Amount of Drug Excreted in Urine From Time Zero to Infinite Time (Aeinf): Part 1

    Aeinf is the cumulative amount of study drug excreted into urine from time of dosing extrapolated to time infinity.

    Time frame: 0-1, 1-2, 2-4, 4-12, and 12-24 hours post dose

  19. Renal Clearance (CLr): Part 1

    The CLr is the renal clearance of the drug.

    Time frame: 0-1, 1-2, 2-4, 4-12, and 12-24 hours post dose

Secondary outcomes

  1. Bond & Lader Visual Analogue Scale (VAS) Score: Part 1 and Part 3

    The VAS is a participant rated scale, made up of 16 (items) pairs of alternative descriptors of mood and attention at either end of a 10 cm line. The item score ranges from 0 to 100, with a high score reflecting a high level of anxiety, sedation or dysphoria.

    Time frame: Days -1, 1, 2 and 3

  2. Karolinska Sleepiness Scale (KSS) Score: Part 1 and Part 3

    The KSS is a participant-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 'extremely alert' (1) to 'very sleepy, great effort to keep awake, fighting sleep' (9).

    Time frame: Days -1, 1, 2 and 3

  3. Profile of Mood States (POMS) Score: Part 1 and Part 3

    The POMS is a self-administered scale that assesses individuals' mood states. This is a validated scale to measure positive and negative mood states. The POMS contains 30 items describing the feeling/mood state rated by participants on a 5-point scale (where, 0=not at all and 4=extremely). The greater the score, the greater the corresponding mood state.

    Time frame: Days -1, 1, 2 and 3

  4. Body Sway: Part 1

    Body sway will be used to measure body movements, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, alcohol, and benzodiazepines. It will be measured either using a stabilometric platform or a pot string meter based on the Wright ataxiameter.

    Time frame: Days -1, 1, 2 and 3

  5. Cognitive Test Battery: International Shopping List Test (ISLT): Part 1

    The ISLT is a measure of Verbal Learning. The test measures total number of correct responses remembering the word list on 3 consecutive trials at a single assessment. Higher score indicates better performance.

    Time frame: Days -21 to -2, Day -1, and Day 1 (6 hours post dose)

  6. Cognitive Test Battery: Groton Maze Learning Test (GMLT): Part 1

    GMLT is a measure of Executive Function and Spatial Learning. The test measures total number of errors made while locating and learning 28 step pathway hidden beneath a 10\*10 grid on 5 consecutive trials during a single session. Lower score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Day 1 (2, 4, 6, and 12 hours post dose), and Day 2 (24 hours post dose)

  7. Cognitive Test Battery: Detection Task (DET): Part 1

    DET is a measure of Psychomotor Function. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Day 1 (2, 4, 6, and 12 hours post dose), and Day 2 (24 hours post dose)

  8. Cognitive Test Battery: Identification Task (IDN): Part 1

    IDN is a measure of Attention. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Day 1 (2, 4, 6, and 12 hours post dose), and Day 2 (24 hours post dose)

  9. Cognitive Test Battery: One Card Learning Task (OCL): Part 1

    OCL is a measure of Visual Learning. The test measures accuracy of performance; arcsine transformation of the square root of the proportion of correct responses. Higher score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Day 1 (2, 4, 6, and 12 hours post dose), and Day 2 (24 hours post dose)

  10. Cognitive Test Battery: One Back Task (ONB): Part 1

    ONB is a measure of Working Memory. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Day 1 (2, 4, 6, and 12 hours post dose), and Day 2 (24 hours post dose)

  11. Cognitive Test Battery: Groton Maze Learning Test (GMLT) Delayed Recall: Part 1

    GMLT delayed recall is a measure of Delayed Spatial Memory. The test measures number of errors made while locating 28 step pathway hidden beneath a 10\*10 grid after a delay. Lower score indicates better performance.

    Time frame: Days -21 to -2, Day -1, and Day 1 (6 hours post dose)

  12. Cognitive Test Battery: International Shopping List Test Delayed (ISLT-D): Part 1

    ISLT-D is a measure of Delayed Verbal Memory. The test measures total number of correct responses recalling the word list learned initially. Higher score indicates better performance.

    Time frame: Days -21 to -2, Day -1, Predose, Day 1 (6 hours post dose), and Day 2 (24 hours post dose)

  13. Sheehan Irritability Scale (SIS) Score: Part 1 and Part 3

    The SIS is a 7-item self-report rating scale that assess symptoms of irritability, frustration, edginess/impatience, moodiness, anger with self, anger with others and temper during the past hour. Each item is assessed on an 11-point numeric rating scale ranging from 0 (not at all) to 10 (extremely). The SIS total score is calculated by summing of the scores for each of the 7 individual items and ranges from 0 to 70. A higher score indicates greater symptomatology.

    Time frame: Day -1, Day 1 (6 and 12 hours post dose), and Day 2 (24 hours post dose)

  14. Cerebrospinal Fluid (CSF) Biomarkers Level: Brain Derived Neurotrophic Factor (BDNF): Part 3

    BDNF level in the CSF (a CSF biomarker) will be analyzed to evaluate the pharmacodynamic effect of JNJ-64140284.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours post dose

  15. Cerebrospinal Fluid (CSF) Biomarkers Level: Monoaminergic Neurotransmitters and Their Metabolites: Part 3

    Monoaminergic neurotransmitters (such as dopamine, serotonine and \[nor\]adrenaline) and their metabolites (such as homovanillic acid \[HVA\], 3,4-dihydroxyphenyl glycol \[DHPG\], 5-hydroxyindoleacetic acid \[5-HIAA\], 3,4-dihydroxyphenylalanine \[DOPA\], and 3,4-dihydroxyphenylacetic acid \[DOPAC\]) in the CSF (CSF biomarkers) will be analyzed to evaluate the pharmacodynamic effect of JNJ-64140284.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours post dose

07

Study locations

1 site
  • Clinical Pharmacology Unit
    Merksem, 2170, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Sep 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2017
First posted
Jun 8, 2017
StartActual
May 30, 2017
Primary completionActual
Sep 25, 2017
CompletionActual
Sep 25, 2017
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03180762
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
May 30, 2017
Primary completion
Sep 25, 2017
Completion
Sep 25, 2017
Last update
Oct 30, 2018

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JNJ-64140284

Start the discussion